These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 23725287)

  • 1. Radioimmunotherapy for high-grade glioma.
    De Bonis P; Lofrese G; Anile C; Pompucci A; Vigo V; Mangiola A
    Immunotherapy; 2013 Jun; 5(6):647-59. PubMed ID: 23725287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends.
    Steiner M; Neri D
    Clin Cancer Res; 2011 Oct; 17(20):6406-16. PubMed ID: 22003068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.
    Hdeib A; Sloan A
    Future Oncol; 2012 Jun; 8(6):659-69. PubMed ID: 22764763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basic immunology of antibody targeted radiotherapy.
    Wong JY
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S8-14. PubMed ID: 16979446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunotherapy of prostate cancer.
    Smith-Jones PM
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):297-304. PubMed ID: 15640793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of therapy of solid tumors: brain tumor therapy.
    Zalutsky MR
    J Nucl Med; 2005 Jan; 46 Suppl 1():151S-6S. PubMed ID: 15653663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunotherapy with alpha-particle emitting radionuclides.
    Zalutsky MR; Pozzi OR
    Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):289-96. PubMed ID: 15640792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The promise of targeted {alpha}-particle therapy.
    Mulford DA; Scheinberg DA; Jurcic JG
    J Nucl Med; 2005 Jan; 46 Suppl 1():199S-204S. PubMed ID: 15653670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Technological advances in radioimmunotherapy.
    Dearling JL; Pedley RB
    Clin Oncol (R Coll Radiol); 2007 Aug; 19(6):457-69. PubMed ID: 17537620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients.
    Reardon DA; Zalutsky MR; Bigner DD
    Expert Rev Anticancer Ther; 2007 May; 7(5):675-87. PubMed ID: 17492931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: a phase I study.
    Riva P; Franceschi G; Frattarelli M; Lazzari S; Riva N; Giuliani G; Casi M; Sarti G; Guiducci G; Giorgetti G; Gentile R; Santimaria M; Jermann E; Maeke HR
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3275s-3280s. PubMed ID: 10541375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracavitary radioimmunotherapy of high-grade gliomas: present status and future developments.
    Reulen HJ; Suero Molina E; Zeidler R; Gildehaus FJ; Böning G; Gosewisch A; Stummer W
    Acta Neurochir (Wien); 2019 Jun; 161(6):1109-1124. PubMed ID: 30980242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    Al-Ejeh F; Shi W; Miranda M; Simpson PT; Vargas AC; Song S; Wiegmans AP; Swarbrick A; Welm AL; Brown MP; Chenevix-Trench G; Lakhani SR; Khanna KK
    J Nucl Med; 2013 Jun; 54(6):913-21. PubMed ID: 23564760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic targeted radionuclide therapy: potential new areas.
    Wong JY
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S74-82. PubMed ID: 16979445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioimmunotherapy of brain tumor.
    Paganelli G; Bartolomei M; Grana C; Ferrari M; Rocca P; Chinol M
    Neurol Res; 2006 Jul; 28(5):518-22. PubMed ID: 16808882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma.
    Chérel M; Gouard S; Gaschet J; Saï-Maurel C; Bruchertseifer F; Morgenstern A; Bourgeois M; Gestin JF; Bodéré FK; Barbet J; Moreau P; Davodeau F
    J Nucl Med; 2013 Sep; 54(9):1597-604. PubMed ID: 24003167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of therapy of solid tumors.
    Jhanwar YS; Divgi C
    J Nucl Med; 2005 Jan; 46 Suppl 1():141S-50S. PubMed ID: 15653662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can α-radioimmunotherapy increase efficacy for the systemic control of cancer?
    Allen BJ
    Immunotherapy; 2011 Apr; 3(4):455-8. PubMed ID: 21463184
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.